Loading…

Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells

Osteosarcoma is a common primary malignant tumor of bone, and doxorubicin is one of the most widely used therapeutic drugs. While the problem of doxorubicin resistance limits the long-term treatment benefits in osteosarcoma patients. The role of miRNAs and their target genes in osteosarcoma have bec...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-02, Vol.15, p.1303732-1303732
Main Authors: Wang, Xinru, Ding, Rumeng, Fu, Zhe, Yang, Meng, Li, Duolu, Zhou, Yubing, Qin, Chongzhen, Zhang, Wenda, Si, Liuzhe, Zhang, Jingmin, Chai, Yuna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c420t-7d393db4b3253270d975f9a7b388e6a741934e787e245c67ab44f1290a59a64e3
container_end_page 1303732
container_issue
container_start_page 1303732
container_title Frontiers in pharmacology
container_volume 15
creator Wang, Xinru
Ding, Rumeng
Fu, Zhe
Yang, Meng
Li, Duolu
Zhou, Yubing
Qin, Chongzhen
Zhang, Wenda
Si, Liuzhe
Zhang, Jingmin
Chai, Yuna
description Osteosarcoma is a common primary malignant tumor of bone, and doxorubicin is one of the most widely used therapeutic drugs. While the problem of doxorubicin resistance limits the long-term treatment benefits in osteosarcoma patients. The role of miRNAs and their target genes in osteosarcoma have become increasingly prominent. Currently, there is no report on miR-506-3p reversing doxorubicin resistance by targeting STAT3 in osteosarcoma. The purpose of this study was to investigate the molecular mechanism that overexpression of miR-506-3p reverses doxorubicin resistance in drug-resistant osteosarcoma cells. Doxorubicin-resistant osteosarcoma cells (U-2OS/Dox) were constructed by intermittent stepwise increasing stoichiometry. The target genes of miR-506-3p were predicted by bioinformatics approach and the targeting relationship between miR-506-3p and STAT3 was detected using dual luciferase reporter assay. U-2OS/Dox cells were treated with miR-506-3p overexpression and STAT3 silencing respectively. Then Western blot and RT-qPCR were used to detect the protein and mRNA expression levels of JAK2/STAT3 signaling pathway, drug-resistant and apoptotic associated molecules. The migration and invasion were assessed by cell scratch assay and transwell assay. The cell proliferative viability and apoptosis were investigated by CCK8 assay and flow cytometry assay. U-2OS/Dox cells were successfully constructed with a 14.4-fold resistance. MiR-506-3p is directly bound to the 3'-UTR of STAT3 mRNA. Compared with U-2OS cells, the mRNA expression of miR-506-3p was reduced in U-2OS/Dox cells. Overexpression of miR-506-3p decreased the mRNA expression levels of JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and decreased the protein expression levels of p-JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and conversely increased Bax expression. It also inhibited the proliferation, migration and invasion of U-2OS/Dox cells and promoted cells apoptosis. The results of STAT3 silencing experiments in the above indicators were consistent with that of miR-506-3p overexpression. Overexpression of miR-506-3p could inhibit the JAK2/STAT3 pathway and the malignant biological behaviors, then further reverse doxorubicin resistance in drug-resistant osteosarcoma cells. The study reported a new molecular mechanism for reversing the resistance of osteosarcoma to doxorubicin chemotherapy and provided theoretical support for solving the clinical problems of doxorubicin resist
doi_str_mv 10.3389/fphar.2024.1303732
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_79f9c6924f4c4ff7880219e632d0adba</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_79f9c6924f4c4ff7880219e632d0adba</doaj_id><sourcerecordid>2933463080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-7d393db4b3253270d975f9a7b388e6a741934e787e245c67ab44f1290a59a64e3</originalsourceid><addsrcrecordid>eNpVkU1P3DAQhiPUChDlD3BAOfaSre1x_HGqKtQPJCSkqj1bjj1ejJI4tRME_75ZdkHgy9jvzDwezVtVF5RsAJT-EqY7mzeMML6hQEACO6pOqRDQaEXZhzf3k-q8lHuyHtAaBD-uTkBxRqjWp5W9fcCMj1PGUmIa6xTqIf5uWiIamOqMa7agr316THnpoovjKpZYZjs6rNeXz8u2eZHmOpUZU7HZpcHWDvu-fKo-BtsXPD_Es-rvj-9_rn41N7c_r6--3TRunWVupAcNvuMdsBaYJF7LNmgrO1AKhZWcauAolUTGWyek7TgPlGliW20FRzirrvdcn-y9mXIcbH4yyUbzLKS8NTbP0fVopA7aCc144I6HIJUijGoUwDyxvrMr6-ueNS3dgN7hOGfbv4O-z4zxzmzTg6FEad0yuhI-Hwg5_VuwzGaIZbcPO2JaimEagAsgiqylbF_qciolY3j9hxKz89o8e212XpuD12vT5dsJX1tenIX_i_am7A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933463080</pqid></control><display><type>article</type><title>Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells</title><source>PubMed Central</source><creator>Wang, Xinru ; Ding, Rumeng ; Fu, Zhe ; Yang, Meng ; Li, Duolu ; Zhou, Yubing ; Qin, Chongzhen ; Zhang, Wenda ; Si, Liuzhe ; Zhang, Jingmin ; Chai, Yuna</creator><creatorcontrib>Wang, Xinru ; Ding, Rumeng ; Fu, Zhe ; Yang, Meng ; Li, Duolu ; Zhou, Yubing ; Qin, Chongzhen ; Zhang, Wenda ; Si, Liuzhe ; Zhang, Jingmin ; Chai, Yuna</creatorcontrib><description>Osteosarcoma is a common primary malignant tumor of bone, and doxorubicin is one of the most widely used therapeutic drugs. While the problem of doxorubicin resistance limits the long-term treatment benefits in osteosarcoma patients. The role of miRNAs and their target genes in osteosarcoma have become increasingly prominent. Currently, there is no report on miR-506-3p reversing doxorubicin resistance by targeting STAT3 in osteosarcoma. The purpose of this study was to investigate the molecular mechanism that overexpression of miR-506-3p reverses doxorubicin resistance in drug-resistant osteosarcoma cells. Doxorubicin-resistant osteosarcoma cells (U-2OS/Dox) were constructed by intermittent stepwise increasing stoichiometry. The target genes of miR-506-3p were predicted by bioinformatics approach and the targeting relationship between miR-506-3p and STAT3 was detected using dual luciferase reporter assay. U-2OS/Dox cells were treated with miR-506-3p overexpression and STAT3 silencing respectively. Then Western blot and RT-qPCR were used to detect the protein and mRNA expression levels of JAK2/STAT3 signaling pathway, drug-resistant and apoptotic associated molecules. The migration and invasion were assessed by cell scratch assay and transwell assay. The cell proliferative viability and apoptosis were investigated by CCK8 assay and flow cytometry assay. U-2OS/Dox cells were successfully constructed with a 14.4-fold resistance. MiR-506-3p is directly bound to the 3'-UTR of STAT3 mRNA. Compared with U-2OS cells, the mRNA expression of miR-506-3p was reduced in U-2OS/Dox cells. Overexpression of miR-506-3p decreased the mRNA expression levels of JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and decreased the protein expression levels of p-JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and conversely increased Bax expression. It also inhibited the proliferation, migration and invasion of U-2OS/Dox cells and promoted cells apoptosis. The results of STAT3 silencing experiments in the above indicators were consistent with that of miR-506-3p overexpression. Overexpression of miR-506-3p could inhibit the JAK2/STAT3 pathway and the malignant biological behaviors, then further reverse doxorubicin resistance in drug-resistant osteosarcoma cells. The study reported a new molecular mechanism for reversing the resistance of osteosarcoma to doxorubicin chemotherapy and provided theoretical support for solving the clinical problems of doxorubicin resistance in osteosarcoma.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2024.1303732</identifier><identifier>PMID: 38420199</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>doxorubicin resistance ; JAK2/STAT3 signaling pathway ; miR-506-3p ; osteosarcoma ; Pharmacology ; U-2OS/Dox</subject><ispartof>Frontiers in pharmacology, 2024-02, Vol.15, p.1303732-1303732</ispartof><rights>Copyright © 2024 Wang, Ding, Fu, Yang, Li, Zhou, Qin, Zhang, Si, Zhang and Chai.</rights><rights>Copyright © 2024 Wang, Ding, Fu, Yang, Li, Zhou, Qin, Zhang, Si, Zhang and Chai. 2024 Wang, Ding, Fu, Yang, Li, Zhou, Qin, Zhang, Si, Zhang and Chai</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c420t-7d393db4b3253270d975f9a7b388e6a741934e787e245c67ab44f1290a59a64e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899521/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899521/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38420199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xinru</creatorcontrib><creatorcontrib>Ding, Rumeng</creatorcontrib><creatorcontrib>Fu, Zhe</creatorcontrib><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Li, Duolu</creatorcontrib><creatorcontrib>Zhou, Yubing</creatorcontrib><creatorcontrib>Qin, Chongzhen</creatorcontrib><creatorcontrib>Zhang, Wenda</creatorcontrib><creatorcontrib>Si, Liuzhe</creatorcontrib><creatorcontrib>Zhang, Jingmin</creatorcontrib><creatorcontrib>Chai, Yuna</creatorcontrib><title>Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Osteosarcoma is a common primary malignant tumor of bone, and doxorubicin is one of the most widely used therapeutic drugs. While the problem of doxorubicin resistance limits the long-term treatment benefits in osteosarcoma patients. The role of miRNAs and their target genes in osteosarcoma have become increasingly prominent. Currently, there is no report on miR-506-3p reversing doxorubicin resistance by targeting STAT3 in osteosarcoma. The purpose of this study was to investigate the molecular mechanism that overexpression of miR-506-3p reverses doxorubicin resistance in drug-resistant osteosarcoma cells. Doxorubicin-resistant osteosarcoma cells (U-2OS/Dox) were constructed by intermittent stepwise increasing stoichiometry. The target genes of miR-506-3p were predicted by bioinformatics approach and the targeting relationship between miR-506-3p and STAT3 was detected using dual luciferase reporter assay. U-2OS/Dox cells were treated with miR-506-3p overexpression and STAT3 silencing respectively. Then Western blot and RT-qPCR were used to detect the protein and mRNA expression levels of JAK2/STAT3 signaling pathway, drug-resistant and apoptotic associated molecules. The migration and invasion were assessed by cell scratch assay and transwell assay. The cell proliferative viability and apoptosis were investigated by CCK8 assay and flow cytometry assay. U-2OS/Dox cells were successfully constructed with a 14.4-fold resistance. MiR-506-3p is directly bound to the 3'-UTR of STAT3 mRNA. Compared with U-2OS cells, the mRNA expression of miR-506-3p was reduced in U-2OS/Dox cells. Overexpression of miR-506-3p decreased the mRNA expression levels of JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and decreased the protein expression levels of p-JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and conversely increased Bax expression. It also inhibited the proliferation, migration and invasion of U-2OS/Dox cells and promoted cells apoptosis. The results of STAT3 silencing experiments in the above indicators were consistent with that of miR-506-3p overexpression. Overexpression of miR-506-3p could inhibit the JAK2/STAT3 pathway and the malignant biological behaviors, then further reverse doxorubicin resistance in drug-resistant osteosarcoma cells. The study reported a new molecular mechanism for reversing the resistance of osteosarcoma to doxorubicin chemotherapy and provided theoretical support for solving the clinical problems of doxorubicin resistance in osteosarcoma.</description><subject>doxorubicin resistance</subject><subject>JAK2/STAT3 signaling pathway</subject><subject>miR-506-3p</subject><subject>osteosarcoma</subject><subject>Pharmacology</subject><subject>U-2OS/Dox</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1P3DAQhiPUChDlD3BAOfaSre1x_HGqKtQPJCSkqj1bjj1ejJI4tRME_75ZdkHgy9jvzDwezVtVF5RsAJT-EqY7mzeMML6hQEACO6pOqRDQaEXZhzf3k-q8lHuyHtAaBD-uTkBxRqjWp5W9fcCMj1PGUmIa6xTqIf5uWiIamOqMa7agr316THnpoovjKpZYZjs6rNeXz8u2eZHmOpUZU7HZpcHWDvu-fKo-BtsXPD_Es-rvj-9_rn41N7c_r6--3TRunWVupAcNvuMdsBaYJF7LNmgrO1AKhZWcauAolUTGWyek7TgPlGliW20FRzirrvdcn-y9mXIcbH4yyUbzLKS8NTbP0fVopA7aCc144I6HIJUijGoUwDyxvrMr6-ueNS3dgN7hOGfbv4O-z4zxzmzTg6FEad0yuhI-Hwg5_VuwzGaIZbcPO2JaimEagAsgiqylbF_qciolY3j9hxKz89o8e212XpuD12vT5dsJX1tenIX_i_am7A</recordid><startdate>20240214</startdate><enddate>20240214</enddate><creator>Wang, Xinru</creator><creator>Ding, Rumeng</creator><creator>Fu, Zhe</creator><creator>Yang, Meng</creator><creator>Li, Duolu</creator><creator>Zhou, Yubing</creator><creator>Qin, Chongzhen</creator><creator>Zhang, Wenda</creator><creator>Si, Liuzhe</creator><creator>Zhang, Jingmin</creator><creator>Chai, Yuna</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240214</creationdate><title>Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells</title><author>Wang, Xinru ; Ding, Rumeng ; Fu, Zhe ; Yang, Meng ; Li, Duolu ; Zhou, Yubing ; Qin, Chongzhen ; Zhang, Wenda ; Si, Liuzhe ; Zhang, Jingmin ; Chai, Yuna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-7d393db4b3253270d975f9a7b388e6a741934e787e245c67ab44f1290a59a64e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>doxorubicin resistance</topic><topic>JAK2/STAT3 signaling pathway</topic><topic>miR-506-3p</topic><topic>osteosarcoma</topic><topic>Pharmacology</topic><topic>U-2OS/Dox</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xinru</creatorcontrib><creatorcontrib>Ding, Rumeng</creatorcontrib><creatorcontrib>Fu, Zhe</creatorcontrib><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Li, Duolu</creatorcontrib><creatorcontrib>Zhou, Yubing</creatorcontrib><creatorcontrib>Qin, Chongzhen</creatorcontrib><creatorcontrib>Zhang, Wenda</creatorcontrib><creatorcontrib>Si, Liuzhe</creatorcontrib><creatorcontrib>Zhang, Jingmin</creatorcontrib><creatorcontrib>Chai, Yuna</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xinru</au><au>Ding, Rumeng</au><au>Fu, Zhe</au><au>Yang, Meng</au><au>Li, Duolu</au><au>Zhou, Yubing</au><au>Qin, Chongzhen</au><au>Zhang, Wenda</au><au>Si, Liuzhe</au><au>Zhang, Jingmin</au><au>Chai, Yuna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2024-02-14</date><risdate>2024</risdate><volume>15</volume><spage>1303732</spage><epage>1303732</epage><pages>1303732-1303732</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Osteosarcoma is a common primary malignant tumor of bone, and doxorubicin is one of the most widely used therapeutic drugs. While the problem of doxorubicin resistance limits the long-term treatment benefits in osteosarcoma patients. The role of miRNAs and their target genes in osteosarcoma have become increasingly prominent. Currently, there is no report on miR-506-3p reversing doxorubicin resistance by targeting STAT3 in osteosarcoma. The purpose of this study was to investigate the molecular mechanism that overexpression of miR-506-3p reverses doxorubicin resistance in drug-resistant osteosarcoma cells. Doxorubicin-resistant osteosarcoma cells (U-2OS/Dox) were constructed by intermittent stepwise increasing stoichiometry. The target genes of miR-506-3p were predicted by bioinformatics approach and the targeting relationship between miR-506-3p and STAT3 was detected using dual luciferase reporter assay. U-2OS/Dox cells were treated with miR-506-3p overexpression and STAT3 silencing respectively. Then Western blot and RT-qPCR were used to detect the protein and mRNA expression levels of JAK2/STAT3 signaling pathway, drug-resistant and apoptotic associated molecules. The migration and invasion were assessed by cell scratch assay and transwell assay. The cell proliferative viability and apoptosis were investigated by CCK8 assay and flow cytometry assay. U-2OS/Dox cells were successfully constructed with a 14.4-fold resistance. MiR-506-3p is directly bound to the 3'-UTR of STAT3 mRNA. Compared with U-2OS cells, the mRNA expression of miR-506-3p was reduced in U-2OS/Dox cells. Overexpression of miR-506-3p decreased the mRNA expression levels of JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and decreased the protein expression levels of p-JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and conversely increased Bax expression. It also inhibited the proliferation, migration and invasion of U-2OS/Dox cells and promoted cells apoptosis. The results of STAT3 silencing experiments in the above indicators were consistent with that of miR-506-3p overexpression. Overexpression of miR-506-3p could inhibit the JAK2/STAT3 pathway and the malignant biological behaviors, then further reverse doxorubicin resistance in drug-resistant osteosarcoma cells. The study reported a new molecular mechanism for reversing the resistance of osteosarcoma to doxorubicin chemotherapy and provided theoretical support for solving the clinical problems of doxorubicin resistance in osteosarcoma.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38420199</pmid><doi>10.3389/fphar.2024.1303732</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2024-02, Vol.15, p.1303732-1303732
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_79f9c6924f4c4ff7880219e632d0adba
source PubMed Central
subjects doxorubicin resistance
JAK2/STAT3 signaling pathway
miR-506-3p
osteosarcoma
Pharmacology
U-2OS/Dox
title Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20miR-506-3p%20reversed%20doxorubicin%20resistance%20in%20drug-resistant%20osteosarcoma%20cells&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Wang,%20Xinru&rft.date=2024-02-14&rft.volume=15&rft.spage=1303732&rft.epage=1303732&rft.pages=1303732-1303732&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2024.1303732&rft_dat=%3Cproquest_doaj_%3E2933463080%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-7d393db4b3253270d975f9a7b388e6a741934e787e245c67ab44f1290a59a64e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2933463080&rft_id=info:pmid/38420199&rfr_iscdi=true